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Background: Non-adherence to aminosalicylates is observed among 30% to 45% of patients with ulcerative colitis
and increases the risk of relapse. The Health Belief Model is a theoretical model that could offer a broader
perspective to improve patients ? self-medication adherence. This study aimed to develop a screening instrument
based on the Health Belief Model to screen patients with ulcerative colitis who had a high possibility of current
non-adherence to aminosalicylates. The study was also designed to allow examination of factors of non-adherence.
Methods: A multicenter, cross-sectional study was conducted in outpatients diagnosed with ulcerative colitis and
prescribed aminosalicylates. Non-adherence was defined as taking less than 80% of the prescribed dose. We
hypothesized that there was a significant relationship between current aminosalicylate non-adherence and five
components of the HBM: beliefs about taking aminosalicylates, disease characteristics, medication characteristics,
abdominal symptoms, and sociodemographic characteristics. A logistic regression model was applied and the
coefficients converted to a numeric scores in order to develop a screening instrument which could reliably discriminate
non-adherent and adherent subjects.
Results: Non-adherence was observed in 127 (29.6%) of the 429 enrolled subjects. Lower perceptions of belief in
taking aminosalicylates, absence of visible bleeding, eight daily tablets or less taken, and no concomitant use of
thiopurines were related to non-adherence. We then developed a screening instrument comprising 22 items. When
the cut-off point was set at 60, the instrument showed 85.0% sensitivity and 69.2% specificity with an area under the
curve of 0.84 (95% confidence interval = 0.79? 0.91).
Conclusions: The instrument appeared to be reliable for identifying patients with a high possibility of current
non-adherence to aminosalicylates. Further, the instrument may provide useful information for detecting patients with
a high possibility of current non-adherence and for assessing factors of non-adherence. On the other hand, we need to
evaluate disease activity more strictly and examine whether it is included in the screening instrument in the future.
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Ulcerative colitis (UC) is a chronic, idiopathic, inflam-
matory bowel disease (IBD) of the large intestine and its
disease course is characterized by periods of relapse and
remission. Multiple studies have reported the efficacy of
aminosalicylates as first-line therapy for inducing remis-
sion and preventing UC relapses [1,2]. Non-adherence
to aminosalicylates, defined as taking less than 80% of
the prescribed dose, was reported by 30% to 45% of pa-
tients [3,4] and increases the risk of clinical relapse from
2.3- to 5.5-fold [3,5,6]. A systematic review indicated
that a patient ? s beliefs about taking medication were
consistently associated with non-adherence [4]. Identify-
ing patients with the high possibility of current non-
adherence and assessing the individual ? s beliefs about
taking aminosalicylates seem to be key steps toward im-
proving medication adherence.
In real clinical settings, however, it is often difficult to
learn about each patient ? s non-adherence or beliefs
about taking medication. Many physicians try to screen
via interview [7], but patients often prefer not to disclose
their actual state to physicians face to face, resulting in
non-adherent patients being missed and not receiving
further assistance. Thus, it is necessary to developing a
screening instrument that allows healthcare providers to
identify patients who are likely to be currently non-
adherent and assess factors relating to non-adherence.
In examining related factors of non-adherence, a pre-
vious review has shown that health behavioral theories
enable healthcare providers to understand the relation-
ship between patients ? beliefs and non-adherence [8].
The Health Belief Model (HBM) is one theory that can
offer greater insight into motivations to adopt adequate
healthcare behavior such as taking medication [9-11].
The HBM identified five domains within one ? s belief sys-
tem as basis for behavior: 1) perceived susceptibility or
vulnerability to the disease process; 2) perceived severity
of the condition; 3) perceived benefits (belief in efficacy);
4) perceived barriers; and 5) cues to action. The HBM
has been widely used as a theoretical framework for in-
terventions or evaluations that attempt to influence
healthcare behaviors across a broad range of conditions
[12,13]. Previous studies also found that all elements of
the HBM were related to medication adherence [12,14,15].
Assessing factors contributing to non-adherence based on
the HBM in patients with UC would be an important con-
tribution to the development of interventions to improve
medication adherence and prevent relapse.
There is only one instrument focusing on patients ? be-
liefs around medications. Horne et al. developed the
Beliefs about Medicines Questionnaire to assess two
subordinate concepts, which are necessity and concerns
about taking medications [16]. It has been reported that
low adherence has been associated with doubts aboutpersonal need for maintenance treatment in IBD and
concerns about potential adverse effects [17-19]. Other
instruments on medication adherence examine reasons
for non-adherence [20-27], or screen patients with high
risk of non-adherence [20,27]. These instruments do not
typically cover patients? beliefs, such as the patient? s per-
spective regarding their medication or their thoughts on
forgetting medicine. Clearly, there is a need to develop a
screening instrument to assess the high possibility of
non-adherence using a comprehensive, theoretical model.
This study aimed to develop a screening instrument, using
the HBM, for identifying patients with UC who had the
high possibility of current non-adherence to aminosalicy-
lates and assessing factors relating to non-adherence.
Methods
Study design and patients
Patients diagnosed as having UC and attending one of
the outpatient clinics of three hospitals located in urban
Japan were consecutively enrolled in this survey. The re-
cruitment period was from May to December 2012. In-
clusion criteria were: 1) met the criteria for UC; 2) were
over 20 years old; and 3) had been prescribed aminosali-
cylates. Patients were excluded if they 1) were intolerant
to aminosalicylates; 2) had a history of surgery for UC;
3) were unable to complete the questionnaires; 4) had
any serious complication; or 5) participated in other
clinical studies at the time of study entry.
This study was a cross-sectional survey using a self-
administered questionnaire and review of medical records.
After the outpatient visit, the physician introduced the pa-
tient to one of the researchers. The researcher explained
the study protocol to each patient and written informed
consent was obtained before the questionnaire was
handed to the patient. The study was approved by the
Ethics Committees of Yokohama City University Medical
Center, University of Tokyo, and Social Insurance Central
General Hospital. Patients were informed that answers to
the questionnaire were masked to their physicians in order
to reduce the possibility that patients with non-adherence
might decline participation or answer their adherence
more positively than reality.
Data collection
Aminosalicylate non-adherence
We hypothesized that there was a significant relation-
ship between current aminosalicylate non-adherence and
five components of the HBM: beliefs about taking ami-
nosalicylates, disease characteristics, medication charac-
teristics, abdominal symptoms, and sociodemographic
characteristics (Figure 1). The rate of adherence to ami-
nosalicylates during the 7 days prior to study enrollment
was investigated using the method employed in previ-
ous studies [28]. This method was chosen because we
Figure 1 Initial hypothesized model for current non-adherence in this study. UC = ulcerative colitis. This is initial hypothesized model for
aminosalicylate non-adherence and various factors in our study. We assumed the relationships between aminosalicylates non-adherence and 5
categories: beliefs, sociodemographic characteristics, symptoms, disease characteristics, and medication characteristics.
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sible recall bias. Subjects answered a question regarding
the prescribed numbers of aminosalicylate tablets and
missed tablets; the number of tablets was converted to a
dose. Prescribed aminosalicylate dose information was also
obtained from the subject? s medical record. The aminosali-
cylate rate of adherence was calculated using the following
formula:
Adherence rate ? Dpres ‐ Dmiss
Dpres
 100
Dpres ? prescribed dose of aminosalicylates according
to medical record
Dmiss ? Dmiss‐pt ? Dpres‐diff ?

Dmiss‐pt ? doses of aminosalicylates that patients have
been missed quetionnaire? ?
Dpres‐diff ?
Dpres − prescribed dose of aminosalicylates according
to patiens questionaire? ? 
Aminosalicylate non-adherence was defined as taking
less than 80% of the prescribed doses and adherence as
consumption of 80% or more [3,5]. The validity of the 7-
day self-report was confirmed using the pill count method
over 2 months in a group of 32 subjects, separate from the
group of 429 subjects, who were diagnosed with UC, took
aminosalicylates, and were enrolled using the same inclu-
sion and exclusion criteria in this study. Most subjects
were within the accepted range of agreement: all except 1were within the 95% confidence interval (CI) according to
the Bland-Altman method [29].
Beliefs about taking aminosalicylates
An extensive literature review and interviews with re-
search experts in IBD (five physicians, three clinical
nurses, and two research nurses) were conducted result-
ing in the inclusion of 19 items regarding beliefs about
taking aminosalicylates. These items were examined by
six patients and three IBD specialists for face validity
and all concluded that the items were relevant and rep-
resentative of possible beliefs about taking aminosalicy-
lates. The 19 items were then assigned to each of the
five domains of the beliefs about taking aminosalicylates
in the HBM: 1 item for ? perceived susceptibility ? , 1 item
for ? perceived severity ? , 2 items for ? perceived benefit ? ,
12 items for ? perceived barrier ? , and 3 items for ? cues to
action ? (Figure 1). For items related to ? perceived bar-
riers ? , we used the items of ? difficulties in taking amino-
salicylates ? that we developed in a previous study [30].
The items were measured with a 5-point Likert-scale,
with a higher score indicating a lower perception of sus-
ceptibility, severity, or benefit, fewer cues to action, and
a higher perception of barrier.
Disease, medication, and sociodemographic characteristics
and abdominal symptoms
The following information was collected from medical
records or asked in the questionnaire: disease character-
istics (duration of UC, family history, duration of current
remission, disease region by recent colonoscopy); medica-
tion characteristics (type of aminosalicylate, times of day
at which the drugs were taken, daily number of tablets
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apy); and abdominal symptoms (stool consistency, bowel
movements, urgency, pain, visible bleeding). Quantitative
variables were categorized based on previous studies [4],
or using their median. Subjects were also asked their
sociodemographic characteristics (gender, age, employ-
ment, marital status, educational level, and living situ-
ation) in the questionnaire.
Statistical analysis
Descriptive statistics were shown as mean and standard
deviation (SD) for continuous variables and as n (%) for
categorical variables. After confirming that Cronbach? s
alphas of ? perceived benefits ? and ? cues to action ? were
above 0.7, responses in items were summed to yield the
total scores. We conducted a univariate logistic regres-
sion analysis to explore factors related to aminosalicylate
non-adherence. The variables with possible association
with non-adherence (p < 0.2) were entered into the ini-
tial multiple logistic regression model. When Spearman ? s
rho was more than 0.7 among the independent variables,
the variable of the smaller p-value was left in the model.
A stepwise multiple logistic regression analysis was then
conducted. The criterion to remain in the multivariate
logistic regression model was set at p < 0.2. The type of
hospital was kept in the model as a control variable.
Variables that stayed in the final logistic regression
model with p < 0.05 were used in the screening instru-
ment for non-adherence. Calibration of the final model
was assessed by the Hosmer-Lemeshow χ2 test. Based on
standardized coefficients calculated in the logistic regres-
sion model, we developed a weighted score as the
screening instrument based on Sullivan ? s method [31].
Briefly, each coefficient was divided by the smallest coef-
ficient and each quotient rounded to the nearest whole
number. Each subject ? s score was then calculated by
summing up the points of all variables. The sum of these
points was used as the screening instrument for non-
adherence.
Discriminability of the screening instrument was assessed
by drawing a receiver-operating characteristic (ROC)
curve and calculating the area under the curve (AUC).
The cut-off point for detecting patients with current non-
adherence in the screening instrument was determined as
a target for the point at the intersection of the inverse cu-
mulative frequency distribution curve and the cumulative
frequency distribution curve. The screening instrument
was also assigned to differentiate risk classes by quartile,
and the prevalence of current non-adherence was com-
pared using the Cochran-Armitage test for trend. All stat-
istical tests were two-tailed, and statistical significance was
defined as p < 0.05. All analyses were performed with SAS
version 9.3 for Windows (SAS Institute Inc., Cary, NC,
USA).Results
Subjects
Four hundred and fifty-five patients met the inclusion
criteria. Twenty-six patients were excluded for the fol-
lowing reasons: 8 patients declined entry and 18 were
missing more than 20% of items in the questionnaire.
Thus, 429 subjects were included in the final analyses.
The valid response rate was 95.9% (Table 1). A total of
127 (29.6%) subjects were classified as non-adherent.
The mean adherence rate in all subjects was 85.9% with
a SD of 17.3. The mean age was 39.9 years, and 56.6%
were male. The mean prescribed aminosalicylate dose
was 3.5 grams per day. One hundred and sixteen sub-
jects (27.0%) had visible bleeding. Cronbach? s alphas of
? cue to action? and ? perceived benefits ? in beliefs about
taking aminosalicylates were 0.72 and 0.71, respectively;
therefore responses to those items were summed to yield
a total score for each of these domains.
Related factors for current non-adherence
Based on the results of univariate logistic regression ana-
lyses, the following factors were included in the multi-
variate logistic regression analyses: all domains in the
beliefs about taking aminosalicylates; the length of
current remission; disease region by recent colonoscopy;
daily number of tablets taken; visible bleeding; following
current concomitant therapy: oral corticosteroids, thiopur-
ines, and biologics; employment status; (Table 1). Because
there was a significant association between daily number
of tablets taken and daily prescribed dose (rs = 0.74, p <
0.01), we used daily number of tablets taken rather than
daily prescribed dose.
All domains in the beliefs about taking aminosalicy-
lates remained in the final logistic regression model
when other factors were adjusted (Table 2). Other fac-
tors remaining in the model were absence of visible
bleeding, 8 daily tablets or less taken, and no concomi-
tant use of thiopurines.
Development of the screening instrument for current
non-adherence based on HBM
The risk score weights based on each factor ? s coefficient
in the final multivariate logistic regression model are
shown in Table 2. Each coefficient was divided by the
smallest coefficient, which was ? perceived barrier ? , and
each quotient was rounded to the nearest whole num-
ber. The screening instrument consists of 22 variables
and the range of the overall score was 0 to 153, with a
higher score indicating a higher possibility of current
non-adherence. The mean score and SD were 61.5 and
18.9 (range: 7 ? 109). The ROC curve of the total score is
shown in Figure 2 (AUC = 0.84, 95% CI = 0.79 ? 0.91).
The instrument showed a sensitivity of 85.0 and specifi-
city of 69.2 when a cut-off point of 60 was used. When
Table 1 Subject characteristics and univariate logistic regression analysis of factors associated with non-adherence
(N = 429)
n (%) or Mean ? SD 1 OR2 95% CI3 p value
Beliefs about taking aminosalicylates
Susceptibility [0-4] 1.5 ? 0.9 1.61 1.28 ? 2.02 <0.01
Severity [0-4] 0.7 ? 1.0 2.22 1.78 ? 2.75 <0.01
Benefits [0-8] 2.5 ? 1.7 1.32 1.17 ? 1.49 <0.01
Barriers [0-48] 21.3 ? 9.9 1.11 1.07 ? 1.13 <0.01
Cues to action [0-12] 4.6 ? 2.7 1.20 1.10 ? 1.30 <0.01
Disease characteristics
Duration of UC: Less than 5 years [more than 5 years] 143 (33.4) 1.20 0.76? 1.86 0.44
Family history: Absence [presence] 409 (95.3) 0.98 0.37? 2.61 0.96
The duration of current remissiona: More than 3 months [less than 3 months] 330 (77.3) 1.57 0.92? 2.66 0.09
Disease region by recent colonoscopyb: Rectum [total, left-side] 113 (26.4) 1.54 0.98? 2.43 0.06
Medication characteristics
Aminosalicylates
Type of aminosalicylatesc: Mesalazine [salazosulfapyridine] 130 (32.8) 1.02 0.64? 1.61 0.94
Times of day at which the drugs were taken: 278 (64.8) 1.14 0.74? 1.77 0.55
2 times or less [3 times or more]
Number of tablets/day: 8 tablets or less [9 tablets or more] 216 (50.3) 1.79 1.18? 2.73 <0.01
Prescribed dose (g/day) 3.5 ? 0.9 0.75 0.59 ? 0.95 0.02
Current concomitant therapy
Topical aminosalicylates: Absence [presence] 301 (70.2) 1.11 0.70? 1.75 0.66
Oral corticosteroids: Absence [presence] 404 (94.2) 2.30 0.77? 6.84 0.13
Topical corticosteroids: Absence [presence] 395 (92.1) 1.68 0.71? 3.97 0.23
Thiopurines: Absence [presence] 369 (86.0) 2.32 1.14? 4.39 0.02
Calcineurin inhibitors: Absence [presence] 410 (95.6) 1.19 0.42? 3.37 0.78
Leukocyte apheresis: Absence [presence] 421 (98.1) 1.27 0.25? 6.36 0.77
Biologics: Absence [presence] 403 (93.9) 2.41 0.82? 7.16 0.11
Abdominal symptoms
Stool consistency: Formed [liquid] 375 (87.4) 0.99 0.53? 187 0.99
Bowel movements/day: 3 times or less [4 times or more] 178 (41.5) 1.22 0.80? 1.85 0.36
Urgency: Absence [presence] 239 (55.7) 1.21 0.80? 1.85 0.37
Pain: Absence [presence] 288 (67.1) 0.89 0.58? 1.38 0.61
Visible bleeding: Absence [presence] 313 (73.0) 1.65 1.003? 2.71 0.04
Sociodemographic characteristics
Gender: Male [female] 243 (56.6) 0.87 0.58? 1.33 0.53
Age 39.9 ? 12.5 0.99 0.97 ? 1.01 0.27
Employment: Full time job, family-operated business
[part time job, student, housewife, unemployed]
243 (56.6) 1.32 0.87? 2.02 0.19
Marital status: Married [unmarried, divorced, widowed] 251 (41.5) 0.92 0.60? 1.41 0.71
Educational level: Junior high school, high school,
vocational school, junior college [college or higher]
207 (48.2) 0.93 0.61? 1.40 0.71
Living situation: Living alone [living with someone] 68 (15.9) 1.14 0.65? 1.98 0.65
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Table 1 Subject characteristics and univariate logistic regression analysis of factors associated with non-adherence
(N = 429) (Continued)
Hospital
Hospital B [A] 239 (55.7) 1.10 0.65? 1.85 0.72
Hospital C [A] 87 (20.3) 1.72 0.93? 3.19 0.10
Information in [brackets] are reference categories.
an = 427, bn = 428, cn = 397 (32 subjects were prescribed two kinds of aminosalicylates and not included in this analysis).
1SD: standard deviation, 2OR: odds ratio, 3CI: confidence interval.
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current non-adherence rate increased significantly with
score strata (p < 0.01) (Figure 3). The final screening in-
strument is shown in the Additional file 1.Discussion
We developed a screening instrument for current ami-
nosalicylate non-adherence and examined factors of
non-adherence among patients with UC using the HBM.
By using this screening instrument, healthcare providers
might be able to identify patients who need support
preferentially and simultaneously assess their beliefs
around taking aminosalicylates. An additional benefit of
this instrument is that patients can complete it by them-
selves. Our results show that this screening instrument
may be useful and contribute to enhancing aminosalicy-
late adherence in clinical practice.Table 2 Multivariate model for non-adherence and risk score
Variables Coefficients O
(










Absence [presence] 0.74 2
Number of tablets/day
8 tablets or less [9 tablets or more] 0.60 1
Hospital
Hospital B [A] 0
Hospital C [A] 1
Information in [brackets] are reference categories. Hosmer-Lemeshow statistics = 9.3
aThe method described by Sullivan et al. [31] was used to calculate the risk score w
the final logistic regression model (in our model, this is barrier). Step 2: Round this
weight of susceptibility, its coefficient of 0.58 was divided by the 0.09, which was th
to its nearest integer resulted in 6 for the score weight of this variable. Each subjec
all variables.In this study, the AUC of this non-adherence screen-
ing instrument was 0.84 (95% CI = 0.79? 0.91), and the
non-adherence rate steadily increased with advancing
score of the instrument using the quartile groups. These
results imply that the instrument has the ability to dis-
tinguish between current non-adherent and adherent
patients. Further studies using this instrument would
confirm its practical validity regarding whether or not it
is in fact useful in identifying high risk populations.
All domains in the beliefs about taking aminosalicy-
lates as well as other clinically important factors were
identified as related to current non-adherence, underlining
the importance of examining these factors for detecting
non-adherence. Relationships between patients? percep-
tion and health behaviors have also been reported in previ-
ous studies. For example, Janz and Becker found that
awareness of susceptibility was one of the predictors (al-
beit the weakest) of behaviors [11]. Other studies reported(N = 426)
dds ratio
95% confidence interval)
p value Risk score
weightsa
.78 (1.32? 2.42) <0.01 6
.35 (1.82? 3.05) <0.01 9
.13 (0.96? 1.33) 0.15 1
.10 (1.06? 1.13) <0.01 1
.14 (1.06? 1.13) 0.02 1
.54 (1.33? 4.86) <0.01 10
.10 (0.88? 5.05) <0.01 8
.92 (1.12? 3.30) 0.02 7
.59 (0.29? 1.19) 0.14
.81 (0.82? 4.00) 0.14
6 (degree of freedom = 8, p = 0.31).
eight: Step 1: Divide each regression coefficient by the smallest coefficient in
quotient to the nearest whole number. For example, to calculate the score
e less perceived barrier, resulting in a quotient of 6.44. Rounding this quotient
t ? s overall screening instrument was then calculated by summing the points of
Figure 2 Receiver operating characteristic curve for the screening instrument for non-adherence. This is the Receiver Operating Characteristic
curve we applied to assess current non-adherence. The area under the curve was 0.84 (95% confidence interval = 0.79 to 0.91). Sensitivity was 85.0%
and specificity was 69.2% when a cut-off value of 60 was applied. N = 426.
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effect on appropriate self-care behaviors including medi-
cation adherence among patients with chronic illness
[13,14], in line with our findings. Higher perceived sever-
ity was also strongly associated with adequate self-care
among patients with chronic illness [11,12]. Rosenstock
noted that the combination of perceived susceptibility













Figure 3 Observed non-adherence rates by score strata. The current n
by the Cochran-Armitage test for trend). N = 127.threat providing the energy or force to act [32]. We
should therefore assess patients ? susceptibility and sever-
ity, and provide support for the patient to have an appro-
priate perception of both domains.
On the other hand, our results showed that perceived
barrier is a cause of non-adherence. This element proved
to be the most powerful of the HBM elements in various
studies [15]. Rosenstock also found that the likelihood of29
77
62-74 75-109
on-adherence rate increased significantly by risk score strata (p < 0.01
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the barriers [32]. We should therefore help patients to
minimize their perceived barriers to taking medication.
For example, memory strategies such as reminders may be
useful in preventing a diminished sense of priority for
medication. Goal setting techniques may also be effective
in reducing barriers in a step-by-step manner [33].
Fewer ? cues to action? , (i.e., communication with family
or healthcare providers about medication and reminders
from them) were another cause of non-adherence. A sys-
tematic review showed that patient-physician discordance
and lack of trust in one? s physician were strongly associ-
ated with non-adherence [34]. Moreover, a previous study
reported that chronically ill patients who received support
or reminders from their families had better outcomes than
patients who did not [35]. Receiving reminders or encour-
agement from healthcare providers and family members
may work as important ? cues to action? to improve
adherence.
We also found that non-adherence increases when
subjects had absence of visible bleeding, fewer than eight
daily tablets, and no concomitant use of thiopurines.
These results were concordant with some previous stud-
ies [4,18]. These conditions taken together suggest a ra-
ther stable disease course and therefore the patient may
forget to take their medications. This may mean that pa-
tients with stable conditions should also be monitored
carefully for possible non-adherence.
There are some limitations to this study. The first
limitation is selection bias: the study was conducted at
IBD specialist clinics in urban areas and subjects may
have been well-educated regarding their disease and
treatment. For example, the non-adherence rate in this
study was about 30%, which is slightly less than in a pre-
vious review [4]. We should evaluate the validity of this
screening instrument under different circumstances and
among different groups of patients to confirm its
generalizability. Second, aminosalicylate adherence was
assessed using a self-report questionnaire and medical
records, and the result may be influenced by recall bias
that is inherent in any retrospective study. As there is no
gold standard method to measure medication adherence,
it is often recommended to assess adherence in multiple
ways and to evaluate agreement between them. We
conducted the present study after confirming subject-
reported adherence using the pill count method. A pre-
vious study also reported that the self-reporting method
had moderate to high agreement with other methods
[36]. Third, we used abdominal symptoms as a surrogate
marker for patients ? disease activity in this study. Disease
activity is one of the most important factors to assess pa-
tients ? non-adherence. Although visible bleeding was
adopted as one of the items of our tool to assess non-
adherence, it might be better if we could use somevalidated disease activity index. We need to evaluate dis-
ease activity more strictly and examine whether it is in-
cluded in the screening instrument. Additionally, we set
a cut-off point to identify as many non-adherent subjects
as possible. Therefore, the false-negative rate was about
14%. However, about 30% of subjects in the good adher-
ence group were identified as having the high possibility
of non-adherence (false-positive). In the future, we
should consider a different cut-off point depending on
the purpose of the instrument. Finally, we developed the
instrument to identify patients with a high possibility of
current non-adherence rather than predicting the risk of
future non-adherence. Further prospective research
would be needed to evaluate its ability to predict future
non-adherence.
Conclusions
We have developed a screening instrument for identify-
ing patients with UC who had a high possibility of
current aminosalicylate non-adherence and for assessing
factors influencing non-adherence, using the framework
of the HBM. All dimensions in the HBM were identified
as related to current non-adherence. Based on our
screening instrument, which had acceptable perform-
ance, subjects who were currently non-adherent were
identified with high sensitivity. The instrument will pro-
vide useful information for detecting subjects with the
high possibility of current non-adherence and for asses-
sing them in order to improve their adherence.
Additional file
Additional file 1: The screening instrument to identify UC patients
with a high possibility of current non-adherence to aminosalicylate
medication. Description of data: This is the screening instrument to
identify UC patients with a high possibility of current non-adherence to
aminosalicylate medication based on the Health Belief Model. The range
of this model is from 0 to 153. A patient whose scores more than 60 is
believed to have a high possibility of current non-adherence.
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